We earlier identified a lysine to arginine transition at residue 303 (K303R) in estrogen receptor alpha (ERa) in invasive breast cancers, which confers resistance to the aromatase inhibitor (AI) anastrozole (Ana) when expressed in MCF-7 breast cancer cells. Here, we show that AI resistance arises through an enhanced cross talk of the insulin-like growth factor receptor-1 (IGF-1R)/insulin receptor substrate (IRS)-1/Akt pathway with ERa, and the serine (S) residue 305 adjacent to the K303R mutation has a key function in mediating this cross talk. The ERa S305 residue is an important site that modifies response to tamoxifen; thus, we questioned whether this site could also influence AI response. We generated stable transfectantsexpressing wild-type, K303R ERa or a double K303R/ S305A mutant receptor, and found that the AI-resistant phenotype associated with expression of the K303R mutation was dependent on activation of S305 within the receptor. Ana significantly reduced growth in K303R/ S305A-expressing cells. Preventing S305 phosphorylation with a blocking peptide inhibited IGF-1R/IRS-1/Akt activation and also restored AI sensitivity. Our data suggest that the K303R mutation and the S305 ERa residue may be a novel determinant of AI response in breast cancer, and blockade of S305 phosphorylation represents a new therapeutic strategy for treating tumors resistant to hormone therapy.
Introduction
Aromatase inhibitors (AIs) have become the choice for first-line hormonal therapy of estrogen receptor alpha (ERa)-positive breast cancer in post-menopausal women. However, many patients are initially refractory or acquire resistance to AI treatment. The mechanisms responsible for the development of resistance remain poorly defined. Several mechanisms have been proposed, including the loss of ERa expression or function (Encarnacion et al., 1993) , alterations in the balance of regulatory cofactors, increased oncogenic kinase signaling (Blume-Jensen and Hunter, 2001) , and deregulated cell proliferation (Evan et al., 1995) . Resistance may also result from altered expression of growth factorsignaling pathways, such as insulin-like growth factor receptor-1 (IGF-1R) and human epidermal growth factor receptor ERBB2, that serve to stimulate estrogen-independent growth (Martin et al., 2003; Schiff et al., 2004; Sabnis et al., 2005; Staka et al., 2005) .
The IGF-1R is a receptor tyrosine kinase that is activated by its ligands, IGF-1, IGF-2, and insulin (Foulstone et al., 2005) . Activation of kinase activity results in autophosphorylation of the receptor, phosphorylation of downstream substrates, such as insulin receptor substrate (IRS1-4) proteins, and consequent stimulation of signaling cascades, such as the MAPK and PI3K/Akt pathways (Backer et al., 1992; Skolnik et al., 1993) . IGF-1R and IRS-1 are often coexpressed with ERa in hormone-dependent breast cancer cells, and epidemiological studies suggest a positive correlation between IGF-1 serum levels and breast cancer risk (Hankinson et al., 1998) . Accordingly, a number of IGF-1R inhibitors have entered into human clinical trials (Sachdev and Yee, 2007) .
We have earlier identified a frequent somatic mutation at nucleotide 908 of ERa (A908G) in premalignant and invasive breast cancers (Fuqua et al., 2000; Herynk et al., 2007) . This mutation introduces a lysine to arginine substitution at residue 303 (K303R) of ERa, and confers the ability for enhanced breast tumor cell growth in low estrogen levels and resistance to the nonsteroidal AI anastrozole (Ana) and tamoxifen (Tam) (Barone et al., 2009; Giordano et al., 2010) . The mutation resides at a region of major post-translational modifications (acetylation, ubiquitination, sumoylation, and metylation) adjacent to the S305 phosphorylation site. Several studies have identified the ERa S305 as an important phosphorylation site that modifies response to Tam in breast tumors (Michalides et al., 2004; Rayala and Kumar, 2007; Holm et al., 2009 ). Phosphorylation of S305 has also been implicated in ligand-independent ERa activation (Tharakan et al., 2008) . The K303R ERa mutation is a more efficient substrate for phosphorylation of S305 by cAMP-dependent protein kinase (PKA), and its phosphorylation is an important determinant of enhanced estrogen hypersensitivity associated with this mutation (Cui et al., 2004) .
In this report, the contribution of the ERa S305 site to AI response will be evaluated to determine whether its site-specific phosphorylation can also result in escape from AI therapy. Our results suggest a dynamic interplay between the K303R ERa mutant, S305 phosphorylation, and IGF-1R-signaling pathways resulting in enhanced cell growth and AI resistance (AI R ).
Results

Gene transcription patterns of K303R ERa-overexpressing cells
We have earlier described a model of ERa-positive MCF-7 breast cancer cells that overexpress the K303R ERa mutant receptor along with aromatase, and reported that expression of the mutant conferred resistance to the AI Ana (Barone et al., 2009) . As shown in Figure 1a , cells expressing the K303R receptor expressed a 66 kDa endogenous ERa protein, along with a 96 kDa receptor representing the exogenously added mutant tagged with yellow-fluorescent protein (YFP). Increased aromatase protein expression was observed in MCF-7 Arom 1 (one clone stably expressing aromatase) and K303R Arom 1 (one clone coexpressing the YFP-K303R mutant and aromatase) cells. To identify genes whose expression was associated with the development of AI R , we compared RNA isolated from K303R Arom 1-expressing cells with wild-type (WT)-expressing cells using expression microarray analysis. Gene-expression analyses showed marked changes in the expression of insulin/IGF family members between the two cell lines based on pathway analysis ( Figure 1b and Table 1 ). We found that K303R ERa mutant expression induced genes that positively regulate IGF signaling (insulin-like growth factor-1: IGF-1, insulin receptor: INSR, IRS-1 and -2: IRS-1 and IRS-2) and suppressed genes that negatively regulate this pathway (insulin-like growth factor-binding protein 3 and 5, IGFBP3-5) (McGuire et al., 1992; Umayahara et al., 1994; Salerno et al., 1999) . We also observed increased expression of JAK2 kinase and the transcription factors fos and STAT1. The two clones had equivalent levels of ERa RNA. These data suggest increased activation of the IGF-signaling pathway in mutant-expressing cells that may be related to increased transcriptional activity of the mutant receptor (Barone et al., 2009) . K303R/S305 ERa residues and aromatase inhibitor resistance I Barone et al IGF-1-signaling pathway activation in K303R ERa-overexpressing cells To validate the gene expression profile identified in the microarray study, specific transcript levels were examined using quantitative real-time PCR, choosing to validate genes on the basis of their potential regulatory function in mediating IGF signaling. For instance, IRS-1 is the predominant molecule activated in response to IGF-1 stimulation, and it has been shown that downregulation of IGF-binding proteins is a mechanism by which estrogen can increase IGF responses. We found a significant increase in IRS-1 mRNA and a significant decrease in IGFBP3 mRNA in K303R Arom 1-expressing cells (Figure 2a ). We next determined whether this altered gene expression resulted in increased phosphorylation and activation of IGF signaling. Cells were maintained under estrogen-depleted conditions, treated with IGF-1, and analyzed for phosphorylation of IGF-1R and IRS-1 (Figure 2b ). MCF-7 Arom 1-expressing cells showed low basal levels of pIGF-1R and pIRS-1 that were increased with IGF-1 treatment. In contrast, K303R-expressing cells showed that elevated constitutive phosphorylation of IGF-1R and IRS-1 further increased with IGF-1. The increase in IGF-1R/IRS-1 phosphorylation resulted in increased phosphorylation of downstream Akt. As expression of exogenous ERa alone might contribute to the increase in IGF activation, we also stably transfected MCF-7 Arom 1-expressing cells or ERa-negative, aromatase-positive CHO cells with an expression vector for YFP-WT ERa. Pools expressing exogenous WT or mutant receptor were evaluated for IGF-1 growth factor-signaling activation. Our results show that the expression of the mutant receptor in different backgrounds and at differing levels of receptor induced elevated constitutive and IGF-1-mediated phosphorylation of IGF-1R/IRS-1/Akt signaling (Figure 2c ).
ERa can bind to IGF-1R (Song et al., 2004) . We have earlier shown that the mutant receptor exhibited altered binding with several regulatory proteins, such as the TIF-2 coactivator, the p85a regulatory subunit of PI3K, and the ERBB2 receptor compared with WT ERa (Fuqua et al., 2000; Barone et al., 2009; Giordano et al., 2010) . To examine whether the mutation might alter binding with the IGF-1R, we transiently transfected CHO cells with YFP-tagged ERs, and coimmunoprecipitation studies were performed. Enhanced binding of IGF-1R to the K303R ERa was observed in the absence of estrogen (Figure 2d ). We also confirmed this enhanced binding by immunoprecipitation of Shc, a key component in mediating ERa-IGF-1R interaction (Song et al., 2004) (Figure 2e ).
We next evaluated whether activation of the IGF pathway by the K303R mutation could enhance the effects of IGF-1 on growth using anchorage-independent growth assays (Figure 2f ). Cells were plated in soft agar, and treated with IGF-1 (0.1 or 10 ng/ml) and the aromatase substrate androstenedione (AD). As earlier shown (Barone et al., 2009) , control basal growth of mutant-expressing cells was significantly elevated compared with WT-expressing cells; IGF-1 treatment at 10 ng/ml, and AD treatment increased the number of colonies in both cells. However, growth stimulation was not observed with low IGF-1 treatment (0.1 ng/ml) in WT cells, whereas IGF-1 at this concentration significantly enhanced mutant growth. Estrogen and IGF-1 are potent mitogens for ERa-positive breast cancer cells, and addition of both may result in additive or synergistic effects (Lee et al., 1999) . In WT-expressing cells, only AD þ IGF-1 at 10 ng/ml increased colony numbers, compared with AD-or IGF-1 alone-stimulated growth. In contrast, in mutant-expressing cells, the combination of AD and IGF-1 at both concentrations increased growth, which was greater than either ligand alone. Therefore, K303R mutant expression was associated with increased IGF-signaling activation, and increased sensitivity to IGF-1 stimulation.
AI
R and the IGF-1R pathway Earlier studies have proposed a dynamic interplay between ERa and several signal transduction pathways, such as IGF-1R and ERBB2, as mechanisms responsible for acquired resistance in breast cancer cells (long-term estrogen-deprived cells, Tam, or letrozole-resistant cells) (Martin et al., 2003; Schiff et al., 2004; Jelovac et al., 2005; Staka et al., 2005) . Therefore, we addressed whether the activated IGF signaling we observed in our model may represent a potential mechanism of AI R . First, we examined the activation of IGF-1R/IRS-1/Akt in cells treated with AD and Ana (Figure 3a , left panel). Representative probesets from pathway analysis showing gene expression changes in the insulin signaling along with the P-value and the fold change of K303R-expressing cells compared with wild-type cells. Only genes at a fold change >2 are shown. In cases where the same genes were deemed significant across multiple probesets, only one is shown.
K303R/S305 ERa residues and aromatase inhibitor resistance I Barone et al WT ERa-expressing cells showed increased pIGF-1R/ pIRS-1/pAkt levels after AD treatment that was reduced with Ana co-treatment. In contrast, the mutant-expressing cells showed elevated constitutive IGF-1R/IRS-1/Akt phosphorylation that was not affected by AD and Ana treatments. Similar results were obtained in stably transfected pools ( Figure 3a , right panel) and transiently transfected (Supplemental Figure  1 ) MCF-7 Arom 1 cells expressing equal amount of exogenous WT or mutant receptor.
To further confirm the function of IGF signaling in the AI R phenotype associated with mutant ERa expression, we performed soft agar assays in the presence of the IGF-1R inhibitor AG1024 (Figure 3b ). AG treatment induced only a slight reduction in the relative growth of MCF-7 Arom 1-expressing cells. In contrast, AG completely suppressed the proliferation of mutantexpressing cells, and the combination of Ana and AG resulted in a higher inhibition of mutant-expressing cell growth. To emphasize the specific involvement of the IGF pathway in AI R , we used a clinically useful EGFR inhibitor (gefitinib [Gef], Figure 3b ). Gefitinib was unable to reverse the AI R phenotype in mutantexpressing cells. Our results suggest that enhanced IGF signaling may contribute to the AI R phenotype associated with K303R ERa mutant expression. These results also question how constitutively activated IGF signaling may affect mutant ERa's function?
Phosphorylation at serine 305 of the K303R ERa mutant and IGF-1R cross talk Post-translational modifications of ERa, such as phosphorylation, are important regulatory components of cross talk between different signaling networks. For instance, phosphorylation at S305 by PKA and PAK1 has been implicated in ligand-independent ERa activation, and in Tam-resistance of breast tumors (Michalides et al., 2004; Rayala and Kumar, 2007; Tharakan et al., 2008) . Furthermore, the K303R ERa mutant is a more efficient substrate for phosphorylation by PKA at S305, which enhanced hormone sensitivity and (f) Cells were plated in soft agar and then treated with vehicle (À) or increasing amounts of IGF-1 (0.1 and 10 ng/ml) ± AD 10 nM. Cells were allowed to grow for 14 days, the number of colonies 450 mm was quantified, and the results were graphed. Data are the mean colony number of three plates and are representative of two independent experiments. Bars, s.d. NS, nonsignificant, **Po0.01, ***Po0.0005.
K303R/S305 ERa residues and aromatase inhibitor resistance I Barone et al
Tam-resistant cell growth (Cui et al., 2004; Giordano et al., 2010) .
We first evaluated the phosphorylation status of the S305 residue in either WT-or K303R ERa-expressing cells using immunoblot analysis. As earlier shown (Giordano et al., 2010) , we found a constitutively higher phosphorylation of S305 in the mutant receptor ( Figure 4a ). We then mutated the predicted S305 phosphorylation site to alanine (A) in the K303R ERa construct (K303R/S305A) to eliminate potential phosphorylation at this site, and found that S305A mutation completely abrogated this phosphorylation.
Then, we examined whether there were kinase-specific consensus phosphorylation sites in ER's hinge domain using publicly available software (netphosK1.0 server) from the Center for Biological Sequence Analysis (http://www.cbs.dtu.dk). Our search suggested that the S305 ERa site was a potential Akt phosphorylation site, with a low consensus score, but only in the mutant; also as expected, S305 was identified as a potential consensus PKA site with a high potential score in both WT and K303R ERa receptors (data not shown). As we have shown enhanced Akt signaling in mutant-expressing cells (Barone et al., 2009) , we initially tested whether the mutant receptor could be phosphorylated by recombinant Akt using an in vitro kinase assay with glutathione S-transferase (GST)-ERa hinge fragments deleting the known S167 Akt consensus sequence. Using increasing amounts of the GST-ERa constructs as phosphorylation substrates, we discovered that the K303R ERa mutant was more efficiently phosphorylated in a dosedependent manner compared with WT receptor and S305A mutation completely prevented in vitro phosphorylation by Akt (Figure 4c) . A receptor fragment containing the S167 Akt site was used as a positive Figure 4 The S305 residue of the K303R mutant receptor is a novel Akt phosphorylation site. (a) Lysates from CHO cells transiently transfected with WT, K303R ERa, or K303R/S305A ERa plasmids were analyzed for phosphorylation levels of S305 YFP ERa (pS305) and total nonphosphorylated YFP-ERa using immunoblot analysis. Rho GDIa was used as a control for equal loading and transfer. (b) In vitro Akt kinase assays using increasing concentrations (1, 5, 10 mg) of WT and K303R ERa GST-fusion hinge fragments (residues 253-310) were performed in kinase buffer. Reaction products were analyzed using SDS-PAGE, and phosphorylated ERa bands were visualized by autoradiography. (c) In vitro Akt kinase assays using WT, K303R, and K303R/ S305A ERa GST-fusion fragments. The ERa fragment containing the known S167 site was used as a positive control in the reaction. (d) In vitro Akt kinase assays using WT, K303R ERa GST-fusion fragments were performed in the presence of the S305 blocking or a control (c) peptide. The input GST proteins were visualized with Ponceau S staining (bottom panels).
K303R/S305
To evaluate the specificity of the S305 phosphorylation by Akt kinase, we also performed kinase assays using a selective ERa-blocking peptide of 11 amino acids corresponding to the sequence surrounding S305, along with a negative control peptide (Figure 4d ). Akt kinase failed to phosphorylate the GST-ERa constructs in the presence of the S305 peptide. These findings suggest that the K303R ERa mutation may generate a super-active substrate for Akt kinase phosphorylation at S305, a site that we have earlier shown to be critically involved in the estrogen hypersensitivity of K303R ERa mutant (Cui et al., 2004) .
We next addressed whether S305 phosphorylation could be a determinant of the increased sensitivity to IGF-1 stimulation associated with K303R mutant expression. We generated pools of stable transfectants expressing exogenous WT, K303R, or K303R/S305A receptors in MCF-7 Arom 1-expressing cells, and evaluated for the effects of increasing concentrations of IGF-1 in soft agar assays (Figure 5a ). The basal nonstimulated growth of K303R Arom pools was higher than that of WT ERa-Arom pools, and expression of the K303R/S305A receptor resulted in a reduction in colony number. IGF-1 10 ng/ml increased anchorageindependent growth in all three clones, whereas IGF-1 Figure 5 Inhibition of serine 305 ERa phosphorylation blocked IGF-1R and mutant ERa cross talk. (a, b) MCF-7 WT, K303R, and K303R/S305A Arom P (a) and CHO WT, K303R, and K303R/S305A P (b) pools of stably transfected and overexpressing cells were plated in soft agar and then treated with vehicle, IGF-1 0.1, or 10 ng/ml for 14 days. The number of colonies 450 mm was quantified and data are the mean colony number of three plates and representative of two independent experiments. Bars, s.d. n.s. ¼ nonsignificant, *Po0.01, **Po0.005. Equal expression of protein was determined by immunoblot with anti-ERa and Rho GDIa antibodies (right panel for a and b). (c) Cellular extracts from serum-deprived MCF-7 Arom WT, K303R K303R/S305A P pools of stably transfected and overexpressing cells were analyzed for phosphorylation (p) and expression of IGF-1R, IRS-1 and Akt by immunoblot analysis. Rho GDIa was used as a control for equal loading and transfer. (d) Cells were incubated with the S305 peptide (4 mg/well) for 4 h and were then treated with or without IGF-1 (10 ng/ml) for 5 min. Levels of phosphorylated (p) IGF-1R, IRS-1, and Akt, and total nonphosphorylated proteins were measured in cellular extracts by immunoblot analysis. Blots are representative of three separate experiments. Rho GDIa was used as a control for equal loading and transfer. (e) MTT growth assays in MCF-7 Arom 1 and K303R Arom 1 cells treated for 3 days with vehicle, IGF-1 (10 ng/ml), and/or the S305 peptide (0.6 mg/well). Cell proliferation is expressed as fold change relative to vehicle-treated cells. The data are representative of four independent experiments, each performed in triplicate. Columns, mean. Bars, s.d. *Po0.005 compared with IGF-1 treatment in MCF-7 Arom 1-cells, **Po0.001 compared with vehicle and IGF-1 treatments in K303R Arom1-expressing cells.
K303R/S305 ERa residues and aromatase inhibitor resistance I Barone et al treatment at the lowest concentration (0.1 ng/ml) enhanced growth only in the K303R-expressing cells. Accordingly, expression of the K303R/S305A double mutant reduced the activation induced by AD þ IGF 10 ng/ml and inhibited the increase on growth mediated by AD þ IGF 0.1 ng/ml when compared with K303R ERa expression (Supplemental Figure 2) . To extend these results, we also generated stable transfected pools of YFP-WT, YFP-K303R, and YFP-K303R/S305A ERa in CHO cells (Figure 5b) . Again, the K303R/S305A double ERa mutant-expressing cells exhibited growth similar to WT cells, showing a significant reduction in colony number compared with K303R-expressing cells, and no increase in growth with low doses of IGF-1.
To confirm the function of S305 phosphorylation in IGF-1R-signaling activation, pools of MCF-7 Arom1 cells expressing YFP-WT, YFP-K303R, and YFP-K303R/S305A receptors were analyzed for IGF-1R/ IRS-1/Akt phosphorylation. The exogenous expression of the K303R/S305A mutant was associated with a reduction in pIGF-1R/pIRS-1/pAkt activation compared with K303R receptor (Figure 5c ).
To investigate the function of the S305 residue in K303R ERa's cross talk with IGF-1R, we delivered the S305-blocking peptide to cells, and after IGF-1 treatment, downstream growth factor-signaling activation was analyzed (Figure 5d ). Blockade of phosphorylation at S305 resulted in specific inhibition of IGF-1R/IRS-1/ Akt phosphorylation in mutant-expressing cells, whereas in WT cells, the S305 peptide slightly enhanced IGF-1-mediated activation of pIGF1-R and pAkt. We next examined the effects of the S305-blocking peptide on cell growth using MTT assays (Figure 5e ). Cells were treated with IGF-1 in the presence or absence of the S305-blocking peptide; IGF-1 treatment enhanced cell growth in both cells. Blockade of S305 resulted in a significant reduction in basal and IGF-1-stimulated growth only in mutant cells, whereas in WT ERa Arom cells the S305 peptide was unable to reduce growth. As seen with immunoblot analysis, we actually observed that treatment with IGF-1 plus the S305 peptidestimulated growth compared with IGF-1 treatment alone in WT cells. The reasons for this increase are not presently understood, although the influence of S305 phosphorylation on methylation at K302, and thus the stability of the receptor (Subramanian et al., 2008) or protein acetylation (Cui et al., 2004) are possibilities. These collective data indicate that phosphorylation of the S305 ERa residue may represent a significant downstream-signaling nodule of cross talk between IGF-1R and the mutant receptor.
K303R/S305 ERa residues and AI R
We next questioned whether the K303R/S305 site could influence AI response. Stable pools of WT and mutant receptors were evaluated for the effects of AD and Ana treatments on anchorage-independent growth (Figure 6a ). Inhibition of aromatase activity by Ana caused a significant reduction in AD-stimulated growth in WT ERa Arom P cells, whereas in K303R-expressing cells, Ana was unable to reduce AD-stimulated growth. In the K303R Arom pool, we observed that AD þ Anastimulated growth compared with AD treatment alone (Po0.01), but this increase may be a variable clonal effect in this pool. Expression of the K303R/S305A receptor restored sensitivity to the inhibitory effects of Ana on growth, thus mimicking the same response profile of WT ERa clones. We also obtained similar results in CHO pools stably expressing WT and mutant receptors (Figure 6b) .
Finally, we delivered the S305-blocking peptide to cells, and evaluated its effect on AI response using growth assays (Figure 6c ). Ana treatment decreased AD-stimulated growth in WT cells, but had no effect in mutant-expressing cells. Blockade of S305 phosphorylation using the peptide inhibited Ana þ AD-mediated growth only in mutant-expressing cells. These data suggest that enhanced phosphorylation at S305 within the hinge domain of the receptor might specifically mediate enhanced cell growth and the AI R phenotype associated with K303R mutant expression, and that blockade of ERa phosphorylation may be an effective strategy to reverse resistance to hormone therapy in tumors bearing the ERa mutation.
Discussion
Despite the efficacy of AIs in the treatment of breast cancer, tumors can develop resistance to estrogen deprivation and relapse with recurrent disease. To explore the mechanisms involved in the development of AI R , we recently discovered that expression of a naturally occurring K303R ERa mutation in MCF-7 breast cancer cells conferred resistance to the nonsteroidal AI Ana (Barone et al., 2009) . This somatic mutation (A908G) has been identified in about a third of premalignant lesions, and one-half of invasive breast tumors (Fuqua et al., 2000; Herynk et al., 2007) , although using another detection method, the mutation was identified in only 6% of tumors (Conway et al., 2005) . This transition introduces a lysine to arginine substitution at residue 303 (K303R) within the hinge domain. The region between the DNA binding and the ligand-binding domains, known as the hinge, has long been considered to simply serve as a flexible linker to orient these functional domains. However, it has now been shown that this region is a multifunctional domain that binds co-regulatory proteins, participates in DNA binding, and undergoes post-translational modifications (Cui et al., 2004; Kim et al., 2006; Haelens et al., 2007) . Naturally occurring mutations have also been identified in the hinge of the androgen receptor in prostate cancer and the progesterone receptor in ovarian cancer. These mutations affect acetylation or phosphorylation of the hinge, and result in hyperactive receptors with enhanced hormone sensitivity (Agoulnik et al., 2004; Romano et al., 2006; Deeb et al., 2008) . Our studies also suggest a new critical function for the hinge domain of the K303R ERa mutant receptor. We reported that overexpression K303R/S305 ERa residues and aromatase inhibitor resistance I Barone et al of K303R mutation in MCF-7 breast cancer cells conferred increased sensitivity to subphysiological levels of estrogen, and decreased sensitivity to Tam when engaged in cross talk with growth factor receptor signaling (Fuqua et al., 2000; Giordano et al., 2010) . We also showed that K303R ERa expression conferred resistance to the AI Ana in ERa-positive cells also coexpressing human aromatase; resistance occurred through activation of the PI3K/Akt pro-survival-signaling pathway to which the mutant cells had become 'addicted' for maintenance of growth (Barone et al., 2009) . In this study, we investigated the function of a post-translational modification of the hinge region of the K303R mutant receptor as a determinant of resistance to AI, and as a possible therapeutic target to reverse resistance. Additional biomarkers to identify patients who are resistant to AIs are lacking in clinical practice. Thus, a better understanding of resistance mechanisms may enable accurate prediction of response, which is relevant, as alternative therapeutic strategies are available. To identify genes whose expression was associated with the development of AI R , we performed expression microarray analyses and found increased expression of several IGF activators, such as IRS-1, and decreased expression of specific IGF inhibitors, such as IGFBP3, in the mutant cells. This altered gene expression resulted in enhanced phosphorylation and activation of IGFsignaling molecules, and increased sensitivity to IGF-1 stimulation. We also found an enhanced association between the mutant receptor and IGF-1R, consistent with our earlier observations of enhanced binding of the mutant receptor to other regulatory molecules. This enhanced binding, along with the increased ligandindependent transcriptional activity of the mutant we earlier reported, may help to sustain enhanced bidirectional cross talk between IGF-1R and K303R ERa, further augmenting signaling between these important growth pathways.
Studies have shown that increased signaling through IGF-1R with consequent activation of IRS-1 and the PI3K/Akt survival pathway leads to resistance to Tam and AI treatments (Wiseman et al., 1993; Campbell et al., 2001; Santen et al., 2005) . Indeed, IGF-1R inhibitors have been used to inhibit breast tumor growth and metastasis (Arteaga and Osborne, 1989 ; Burtrum K303R/S305 ERa residues and aromatase inhibitor resistance I Barone et al et al., 2003; Sachdev et al., 2004) . We found that an IGF-1R inhibitor, AG1024, completely suppressed the proliferation of mutant-expressing cells, and the combination of an AI with AG resulted in a greater growth inhibition. These results suggest that the persistence of active IGF-1R signaling may be a functional mechanism of resistance to AI therapies in cells expressing the mutant receptor.
ERa is known to be a target of several posttranslational modifications (Faus and Haendler, 2006) . ERa phosphorylation results from the activation of various cellular kinases and substantially alters its function. For example, ERa can be differentially phosphorylated by Akt and extracellular regulated kinase (Erk1/2) MAPK, resulting in diverse responses to the ligand (Likhite et al., 2006) . Recently, we and others have shown that PKA and PAK1-mediated phosphorylation of ERa S305 affected both estrogen hypersensitivity and Tam response (Cui et al., 2004; Michalides et al., 2004; Rayala and Kumar, 2007) . Our search for kinase consensus sequences identified the S305 site as a novel Akt phosphorylation site in the mutant receptor. Although the target site sequence around S305 is not a perfect match to the consensus target site for Akt (R-x-R-x-x-S/T) (Manning and Cantley, 2002) , it is known for other PKAs that the inclusion of additional amino acids of the same charge in this target site sequence enhanced substrate activity (Brenet et al., 2009) . In addition, Akt may efficiently phosphorylate substrates that conform less rigorously to the requirement for arginine at positions n-3 and n-5 (Ksiezak- Reding et al., 2003) . In vitro Akt kinase assays showed that the K303R ERa mutant was more efficiently phosphorylated compared with WT ERa, and phosphorylation of the K303R mutant receptor at S305 was comparable with S167 phosphorylation. Both, mutation of S305 to A to remove the phosphorylation site, and the use of a selective-blocking peptide mimicking the sequence of ERa surrounding S305, prevented in vitro phosphorylation by Akt. We earlier showed that the mutation leads to enhanced constitutive phosphorylation of Akt, and subsequent phosphorylation of the Akt S167 site within ER (Barone et al., 2009) . Here, we show that activated Akt can also elicit effects on phosphorylation of S305 in the mutant receptor, and that this phosphorylation increased its ligand-independent activity. To study the involvement of S305 phosphorylation in the AI R phenotype associated with the K303R mutation, we generated stable transfectants expressing exogenous K303R/S305A receptor. Double mutant-expressing cells exhibited soft agar growth similar to WT cells, showing a significant reduction of the colony numbers compared with K303R-expressing cells, no increase in anchorage-independent growth under low doses of IGF-1, and a marked sensitivity to Ana. These results suggest a prominent function for the S305 residue in mediating the mutant-resistant phenotype.
Others have synthesized small antagonistic peptides capable of interfering with signaling pathway activation (Rayala et al., 2006; Fontenot et al., 2007; Varricchio et al., 2007) Nakajima et al. (2008) showed that a five amino-acid peptide inhibited ERBB2 signaling, and proliferation equivalent to treatment with the ERBB2-antagonist trastuzumab. The S305 peptide used in this study blocked heregulin-induced S305 ERa phosphorylation, and prevented downstream phosphorylation events in K303R-expressing cells (Giordano et al., 2010) . Thus, the contribution of the S305 site to the AI R phenotype associated with the K303R mutation was also evaluated using the S305-blocking peptide. We found specific inhibition of IGF-1R/IRS-1/Akt phosphorylation, and a significant reduction in basal and IGF-1-stimulated growth in the presence of the S305 peptide in mutant-expressing cells. Importantly, inhibition of IGF-1R and the mutant receptor cross talk by blocking S305 phosphorylation reversed resistance in the mutant cells. Our studies suggest that the K303R/ S305 ERa residues have a crucial function in ERa action in breast cancer by enhancing cross talk between IGF-1R and the mutant receptor, which leads to AI R . We propose a model in which the mutation enhances the ability of the receptor to bind to IGF-1R and activates IRS-1/Akt downstream signaling pathway. Activated Akt in turn phosphorylates ERa at S305 and increases the transcription of IGF-signaling molecules, thus establishing a positive feedback loop between growth factor signaling and ERa to bypass normal endocrine controls and responsiveness (Figure 7) .
The function of S305 phosphorylation in AI R represents a novel mechanism. We speculate that the blockade of this phosphorylation site may be a new therapeutic strategy to block ERa hyperactivation and overcome resistance in mutation-positive patients who are resistant to AI therapy. Figure 7 Model depicting potential cross talk between the ERa and IGF-signaling components in breast cancer cells expressing the mutation. K303R ERa mutant receptor binds to IGF-1R and activates the IGF-1R-signaling cascades, including the IRS-1 and Akt pathways. Activated Akt promotes the phosphorylation of the K303R ERa mutant at the S305 residue, leading to an increase in the transcription of IGF signaling molecules, thus establishing a positive feedback loop between growth factor and steroid receptors that leads to AI R .
IGF-1 Receptor
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Materials and methods
Reagents, hormones, and antibodies 17b-estradiol, 4-androstene-3, 17-dione, and insulin-like growth factor-1 were purchased from Sigma (St Louis, MO, USA). Ana and gefitinib were obtained from Astrazeneca (Macclesfield, England), and AG1024 from Calbiochem (Darmstadt, Germany). Antibodies used for immunoblotting were ERa (Vector Laboratories, Burlingame, CA, USA), Shc, Rho GDIa (Santa Cruz Biotechnology, Santa Cruz, CA, USA), total IGF-1R, IRS-1, Akt, phosphorylated IGF-1R
, Akt (Ser473) (Cell Signaling Technology, Beverly, MA, USA), IRS-1 (Tyr612) (Invitrogen, Carlsbad, CA, USA), and phospho-ER (Ser305) (Upstate, Temecula, CA, USA). Goat anti-mouse or anti-rabbit secondary antibodies were from Amersham Bioscences (Piscataway, NJ, USA).
Plasmids
Generation of the YFP-tagged ERa-expression constructs, YFP-WT, YFP-K303R and YFP-K303R/S305A ERa are described earlier (Cui et al., 2004) .
Cell culture MCF-7 breast cancer cells were cultured as described (Cui et al., 2004) . The aromatase-overexpressing cells MCF-7 Arom and K303R Arom, and CHO or MCF-7 Arom-expressing pools, stably transfected with YFP-WT, YFP-K303R, and YFP-K303R/S305A ERa-expression vectors were generated as described (Barone et al., 2009 Immunoblot analysis Cells were starved in serum-free MEM for 48 h, and treated as indicated before lysis (Herynk et al., 2006) . Equal amounts of cell extracts were subjected to SDS-PAGE, as described (Cui et al., 2004) .
Blocking peptide delivery A blocking peptide of 11 residues ( 298 IKRSKKNSLAL 308 ) surrounding the S305 residue (in bold) of the human ERa was transfected into cells as described (Giordano et al., 2010) .
In vitro Akt kinase assay Expression vectors for GST fusion proteins of WT, K303R, and K303R/S305A ERa hinge region (residues 253-310) were described earlier (Cui et al., 2004) . Kinase assays were performed as published in the supplemental information on the Oncogene website.
Cell proliferation assays
After 48 h of starvation in 5% charcoal-stripped FBS phenol red-free MEM, cell proliferation was assessed using soft agar anchorage-independent or MTT growth assays as described (Barone et al., 2009; Giordano et al., 2010) .
Statistical analysis
Data were analyzed by Student's t-test using the GraphPAD Prism5 software (GraphPad Software, Inc., San Diego, CA, USA).
